Fintel reports that on December 12, 2025, Guggenheim upgraded their outlook for Bristol-Myers Squibb (NYSE:BMY) from Neutral ...

U.S. Food and Drug Administration (FDA) Grants Priority Review to Bristol Myers Squibb's Application for Opdivo® (nivolumab) Plus Chemotherapy Combination for Classical Hodgkin Lymphoma, by Bristol ...

This initiative marks among the BMS Foundation’s first grants in India to increase access to screening and build capacity to ...

The futures are trading mixed as we get set to close out a wild and woolly week that saw a touch of just about everything.

Cobenfy’s efficacy at treating the symptoms of patients with psychosis may vary between subgroups, according to a post-hoc ...

Bristol-Myers Squibb Company (BMY) recently received an upward revision to a “Buy” rating from Seamus Fernandez at Guggenheim, a move that investors view as a significant endorsement amid a ...

Pfizer and Bristol Myers Squibb are deeply out-of-favor drugmakers, but one could be the better turnaround candidate if you ...

Beam Therapeutics Inc. has raked in $255 million in cash from the sale of its spinout, Orbital Therapeutics, to Bristol Myers ...

Emerging evidence hints that daily multivitamins might quietly help certain older adults keep their blood pressure in ...

Gilead Sciences and Arcus Biosciences said on Friday they would stop a late-stage study testing their experimental cancer ...

Guggenheim analyst Seamus Fernandez upgraded Bristol-Myers Squibb Company (NYSE: BMY) from Neutral to Buy and announced a $62 ...

Starton Holdings filed for an initial public offering, as it works to develop a treatment for blood cancers. The clinical-stage biotechnology company plans to offer about 6.7 million shares priced at ...